Viral dynamic modeling during direct acting antivirals against hepatitis C virus: review and perspectives
vendredi 23 novembre 2012, 11h00 - 12h00
Salle de réunion, espace Turing
{{Résumé}}
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and affects nearly 170 million people worldwide. Whereas the previous standard of care with pegylated interferon and ribavirin had a modest effectiveness, the recent approval of two highly potent protease inhibitors and the ongoing development of dozens of direct-acting antiviral agents (DAAs) constitute a major milestone for HCV therapy. Mathematical modeling of viral kinetics under treatment has played an instrumental role in improving our understanding of virus pathogenesis and in guiding drug development. We will review recent viral kinetics studies of DAA therapy and discuss how models developed for DAAs challenge the validity of previous models developed for analyzing viral decline during pegylated interferon and ribavirin.
